
|Videos|June 1, 2013
Dr. Carvajal Describes MEK Inhibition in Uveal Melanoma
Author(s)Richard D. Carvajal, MD
Richard D. Carvajal, MD, a medical oncologist at Memorial Sloan-Kettering Cancer Center, describes the success of MEK inhibition in patients with advanced uveal melanoma using the agent selumetinib.
Advertisement
Richard D. Carvajal, MD, a medical oncologist at Memorial Sloan-Kettering Cancer Center, describes the success of MEK inhibition using the agent selumetinib in patients with advanced uveal melanoma.
The trial exploring selumetinib was the first to discover an effective agent for patients with advanced uveal melanoma. Even though the MEK inhibitor trametinib was recently approved, Carvajal believes clinical trials are still the most appropriate area for treatment with MEK inhibitors in uveal melanoma.
<<<
Advertisement
Related to this article

The IL-12–expressing self-replicating mRNA STX-001 showed a favorable therapeutic window at 100 µg, with regression in both injected and non-injected lesions.

Most of the survival time accrued with RP1 plus nivolumab in the IGNYTE trial was spent in good health among patients with advanced melanoma after anti–PD-1 therapy.

The EC approved every-6-week maintenance dosing and shorter 350-mg infusions for cemiplimab across all 6 EU indications.

Narek Shaverdian, MD, outlines how novel strategies may reshape unresectable stage III NSCLC management.

Experts weigh in on standout breast cancer, lung cancer, melanoma, and kidney cancer data presented at the 2026 ESMO Congress.

Longer follow-up of KANDLELIT-001 supports frontline calderasib plus pembrolizumab in KRAS G12C–mutated metastatic non–small cell lung cancer.

Alissa Cooper, MD, reviews new data for established and emerging antibody-drug conjugate targets in non–small cell lung cancer and argues that payload innovation and better patient selection are the field's greatest needs.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Priority Review to Sonesitatug Vedotin in CLDN18.2+ Gastroesophageal Cancer
2
Dose Optimization, Evidentiary Bars, and Patient Selection Shape Trial Design in EGFR- and HER2-Mutant NSCLC
3
EC Approves Extended Cemiplimab Dosing in Skin, Lung, and Cervical Cancers
4
Defining High-Risk Localized Prostate Cancer and the DASL-HiCaP Trial
5

